Postoperative ctDNA in indicating the recurrence risk and monitoring the effect of adjuvant therapy in surgical non‐small cell lung cancer

Postoperative ctDNA in indicating the recurrence risk and monitoring the effect of adjuvant therapy in surgical non‐small cell lung cancer

Abstract Background Circulating tumor DNA (ctDNA) has emerged as a potential novel biomarker to predict molecular residual disease (MRD) in lung cancer after definitive treatment. Herein, we investigated the value of ctDNA in prognosing risk of relapse and monitoring the effect of adjuvant therapy i...

Full description

Bibliographic Details
Main Authors: Xiaoru Tian, Xingsheng Liu, Kai Wang, Ruotian Wang, Yuanbo Li, Kun Qian, Tengteng Wang, Xin Zhao, Lei Liu, Pei Long Zhang, Yuanyuan Xiong, Jinqiu Rui, Rongrong Chen, Yi Zhang
Format: Article
Language:English
Published: Wiley 2024-04-01
Series:Thoracic Cancer
Subjects:
adjuvant therapy
ctDNA
disease relapse
molecular residue disease
non‐small cell lung cancer
Online Access:https://doi.org/10.1111/1759-7714.15251

Internet

https://doi.org/10.1111/1759-7714.15251

Similar Items